AllSci News
Soligenix’s HyBryte shows improved response and tolerability vs Valchlor in small CTCL study
Soligenix (Nasdaq: SNGX) reported that a small comparative study of synthetic hypericin (HyBryte) versus mechlorethamine (Valchlor) in cutaneous T-cell...
Inovio raises USD 17.5m in underwritten public offering
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a USD 17.5 million underwritten public offering on April 2, 2026, seeking to extend its cash runway as...
Oric's PRC2 inhibitor rinzimetostat combo regimen advances to Phase III trial in mCRPC
ORIC Pharmaceuticals (Nasdaq: ORIC) reported Phase Ib dose optimization data for rinzimetostat in combination with darolutamide in post-abiraterone...
Novo Nordisk follows Lilly's oral GLP-1 approval with data showing Wegovy's weight loss advantage
Novo Nordisk (NVO) reported that oral semaglutide 25 mg (Wegovy) produced approximately 3 percentage points more weight loss than orforglipron in a...
Fore Bio’s plixorafenib receives FDA Breakthrough Therapy status for BRAF-mutated glioma
Fore Biotherapeutics, a registration-stage oncology company headquartered in Philadelphia, Pennsylvania, announced that the FDA has granted Breakthrough Therapy Designation (BTD) to plixorafenib…
Alto discontinues transdermal PDE4 inhibitor after Phase II failure in schizophrenia-linked cognitive impairment
Alto Neuroscience (NYSE: ANRO) reported that ALTO-101 failed to meet its primary EEG or cognitive endpoints versus placebo in a Phase II proof-of-concept...
Shionogi acquires global RADICAVA rights from Tanabe Pharma for USD 2.5b
Shionogi Acquires Global RADICAVA Rights for USD 2.5 Billion from Tanabe Pharma Corporation
A2’s logic-gated, IL-12-tethered CAR-T takes FDA Fast Track for MSLN solid tumors
A2 Biotherapeutics, headquartered in Agoura Hills, California, announced receipt of US FDA Fast Track Designation for A2B543, an autologous logic-gated chimeric antigen…
Gilead Sciences extends deadline for Arcellx tender offer
Gilead Sciences Consolidates Full Ownership of Multiple Myeloma CAR T Programme via USD 120.00 Per Share Acquisition of Arcellx
Alpha Cognition receives USPTO patent for ALPHA-1062 traumatic brain injury treatment method
Vancouver-based Alpha Cognition Inc., (NASDAQ: ACOG), a biopharmaceutical company focused on neurodegenerative disorder therapy, received US Patent No. 12,589,099 from the USPTO,…
FDA approves Eli Lilly’s oral GLP-1 Foundayo for weight loss
The US FDA approved Eli Lilly and Company’s oral GLP-1 receptor agonist orforglipron (Foundayo) on April 1, 2026 for chronic weight management…
Zai Lab and Amgen collaborate on DLL3-targeting dual mechanism strategy for SCLC
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and Amgen (NASDAQ: AMGN) have entered a global clinical trial collaboration and supply agreement to evaluate…
Ray Therapeutics’ RTx-015 optogenetic gene therapy earns RMAT designation for retinitis pigmentosa
Ray Therapeutics, a clinical-stage biopharmaceutical company headquartered in Berkeley, California, has announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT)…
FDA extends review of Orca Bio's Orca-T for hematologic malignancies to July 2026
Orca Bio has announced that the US FDA extended the review timeline for its Biologics License Application (BLA) for Orca-T, an investigational allogeneic...
Nuvation Bio takes global control of IDH1 drug safusidenib through Japan market deal with Daiichi Sankyo
Safusidenib, an oral brain-penetrant inhibitor of mutant IDH1, will now advance under a single global rights holder after Nuvation Bio (NYSE: NUVB) amended...
The AllSci Brief
Systematic R&D and deal news. Daily.